全身炎症综合指数:预测股浅动脉病变腔内治疗后狭窄风险的新型炎症标志物
该回顾性队列纳入632例因症状性外周动脉疾病行腔内治疗的股浅动脉病变患者,142例发生再狭窄。高全身炎症综合指数(AISI)与再狭窄风险增加2.13倍相关,且再狭窄时间更短。AISI或可用于风险分层。
要点
- 再狭窄组AISI中位数显著高于非再狭窄组(909.28 vs. 516.59,P<0.001)。
- 高AISI患者再狭窄风险增加(HR 2.133,95%CI 1.508-3.017,P<0.001)。
- AISI截断值489.64,敏感性57%、特异性56%、AUC 0.623。
核心结论
- AISI是有前景的炎症生物标志物,可预测股浅动脉腔内治疗后再狭窄风险。
研究设计与样本
- 回顾性队列研究,纳入632例因症状性外周动脉疾病行腔内治疗的股浅动脉病变患者。
- AISI计算公式为(中性粒细胞×血小板×单核细胞)/淋巴细胞。
- 采用多因素logistic回归和Cox比例风险模型识别再狭窄独立预测因素。
主要发现
- 632例中142例发生再狭窄。
- 再狭窄组AISI中位数显著高于非再狭窄组(909.28 vs. 516.59,P<0.001)。
- 高AISI患者再狭窄风险增加2.13倍(HR 2.133,95%CI 1.508-3.017,P<0.001),再狭窄时间更短(中位6个月 vs. 12个月)。
- 吸烟、既往干预史、干预类型及支架移植物使用也与再狭窄风险升高相关。
关键数值与推荐
- AISI截断值489.64,敏感性57%,特异性56%,AUC 0.623。
临床怎么用
- 将AISI纳入临床实践可能增强风险分层并指导个体化管理策略。
局限性
- 需前瞻性研究证实这些发现,并进一步探究全身炎症在再狭窄发生中的机制作用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Restenosis of the superficial femoral artery (SFA) following endovascular treatment remains a significant clinical challenge in peripheral artery disease (PAD). This study evaluates the prognostic value of the Aggregate Index of Systemic Inflammation (AISI) as a biomarker for predicting restenosis risk in SFA lesions. METHODS: In a retrospective cohort study, 632 patients undergoing endovascular interventions for symptomatic PAD were analyzed. AISI was calculated as: (neutrophils × platelets × monocytes)/lymphocytes. Patients were divided into 2 groups as those who developed restenosis and those who did not develop restenosis. Multivariate logistic regression and Cox proportional hazards models were used to identify independent predictors of restenosis. RESULTS: Among 632 patients, 142 developed restenosis. The median AISI was significantly higher in the restenosis group compared to the nonrestenosis group (909.28 vs. 516.59, P < 0.001). Patients with high AISI demonstrated a 2.13-fold increased risk of restenosis (hazard ratio: 2.133, 95% confidence interval: 1.508-3.017, P < 0.001) and a shorter time to restenosis (median: 6 months vs. 12 months). Smoking, presence of prior intervention, intervention types, and stent-graft use were also associated with an elevated risk of restenosis. Receiver operating characteristic analysis identified an AISI cutoff value of 489.64 (sensitivity: 57%, specificity: 56%, area under the curve: 0.623). CONCLUSION: AISI is a promising inflammatory biomarker for predicting the risk of restenosis in PAD patients undergoing endovascular treatment of the SFA. Incorporating AISI into clinical practice could enhance risk stratification and guide personalized management strategies. Prospective studies are needed to confirm these findings and further investigate the mechanistic role of systemic inflammation in restenosis development.
引用
- Erdoğan O, Erdoğan T, Panç C, et al. The Aggregate Index of Systemic Inflammation: A Novel Inflammatory Marker for Predicting Restenosis Risk in Superficial Femoral Artery Lesions after Endovascular Treatment. Ann Vasc Surg. 2025. PMID: 40582453. doi:10.1016/j.avsg.2025.06.027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。